Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 4/2020

01-04-2020 | Sinus Surgery | Rhinosinusitis (Section Editor, Joaquim Mullol)

NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets

Authors: Tanya M. Laidlaw, Joshua M. Levy

Published in: Current Allergy and Asthma Reports | Issue 4/2020

Login to get access

Abstract

Purpose of Review

This review summarizes the latest information on the appropriate identification, evaluation, and treatment of patients with nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NSAID-ERD), also known as aspirin-exacerbated respiratory disease (AERD). Within the framework of our understanding of the underlying pathophysiology of NSAID-ERD, we also provide an update regarding new surgical techniques and newly available or upcoming medical therapies that may benefit these patients.

Recent Findings

There have been considerable developments regarding recommendations for both the extent and timing of sinus surgery for NSAID-ERD. The last few years have also given us several new biologic medications that warrant consideration in the treatment of patients with recalcitrant NSAID-ERD. Further clinical trials are underway to investigate additional medications that may decrease the type 2 inflammation that dominates this disease.

Summary

Despite the severe lower respiratory inflammation and recurrent nature of the nasal polyps in patients with NSAID-ERD, significant recent advances now afford much-improved quality of life for these patients. Careful collaboration between Allergy/Immunology and Rhinology specialists is imperative to ensure proper treatment of patients with NSAID-ERD.
Literature
1.
Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006;118(4):773–86 quiz 787-778.CrossRefPubMed
2.
Laidlaw TM, Boyce JA. Aspirin-exacerbated respiratory disease--new prime suspects. N Engl J Med. 2016;374(5):484–8.CrossRefPubMed
3.
White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. N Engl J Med. 2018;379(11):1060–70.CrossRefPubMed
4.
Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135(1):245–52.CrossRefPubMed
5.
Cardet JC, White AA, Barrett NA, Feldweg AM, Wickner PG, Savage J, et al. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2014;2(2):208–13.CrossRefPubMedPubMedCentral
6.
De Schryver E, Derycke L, Campo P, et al. Alcohol hyper-responsiveness in chronic rhinosinusitis with nasal polyps. Clin Exp Allergy. 2017;47(2):245–53.CrossRefPubMed
7.
Divekar R, Hagan J, Rank M, Park M, Volcheck G, O'Brien E, et al. Diagnostic utility of urinary LTE4 in asthma, allergic rhinitis, chronic rhinosinusitis, nasal polyps, and aspirin sensitivity. J Allergy Clin Immunol Pract. 2016;4(4):665–70.CrossRefPubMedPubMedCentral
8.
•• DeGregorio GA, Singer J, Cahill KN, Laidlaw T. A 1-day, 90-minute aspirin challenge and desensitization protocol in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2019;7(4):1174–80. Paper describing protocol for oral aspirin challenge and desensitization. CrossRefPubMed
9.
Pelletier T, Roizen G, Ren Z, Hudes G, Rosenstreich D, Jerschow E. Comparable safety of 2 aspirin desensitization protocols for aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2019;7(4):1319–21.CrossRefPubMed
10.
Mullol J, Picado C. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin N Am. 2013;33(2):163–76.CrossRef
11.
Laidlaw TM, Cahill KN, Cardet JC, et al. A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2018.
12.
Morse JC, Shilts MH, Ely KA, Li P, Sheng Q, Huang LC, et al. Patterns of olfactory dysfunction in chronic rhinosinusitis identified by hierarchical cluster analysis and machine learning algorithms. Int Forum Allergy Rhinol. 2019;9(3):255–64.CrossRefPubMed
13.
•• Smith KA, Orlandi RR, Oakley G, Meeks H, Curtin K, Alt JA. Long-term revision rates for endoscopic sinus surgery. Int Forum Allergy Rhinol. 2019;9(4):402–8. Large database study describing the revision rates for endoscopic sinus surgery and the patient factors that contributed to them. CrossRefPubMed
14.
Mendelsohn D, Jeremic G, Wright ED, Rotenberg BW. Revision rates after endoscopic sinus surgery: a recurrence analysis. Ann Otol Rhinol Laryngol. 2011;120(3):162–6.CrossRefPubMed
15.
Comhair SAA, Bochenek G, Baicker-McKee S, Wang Z, Stachura T, Sanak M, et al. The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease. Respir Res. 2018;19(1):210.CrossRefPubMedPubMedCentral
16.
Stevens WW, Ocampo CJ, Berdnikovs S, Sakashita M, Mahdavinia M, Suh L, Takabayashi T, Norton JE, Hulse KE, Conley DB, Chandra RK, Tan BK, Peters AT, Grammer LC 3rd, Kato A, Harris KE, Carter RG, Fujieda S, Kern RC, Schleimer RP Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease. Am J Respir Crit Care Med 2015;192(6):682–694.
17.
Cahill KN, Murphy K, Singer J, Israel E, Boyce JA, Laidlaw TM. Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2019;143(2):799–803 e792.CrossRefPubMed
18.
Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–81 e671.CrossRefPubMed
19.
Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol. 2008;100:420–5.CrossRefPubMed
20.
Cahill KN, Johns CB, Cui J, Wickner P, Bates DW, Laidlaw TM, et al. Automated identification of an aspirin-exacerbated respiratory disease cohort. J Allergy Clin Immunol. 2017;139(3):819–25 e816.CrossRefPubMed
21.
Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991;143(5 Pt 1):1025–9.CrossRefPubMed
22.
Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012;119(16):3790–8.CrossRefPubMedPubMedCentral
23.
Eastman JJ, Cavagnero KJ, Deconde AS, et al. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2017;140(1):101–108 e103.CrossRefPubMedPubMedCentral
24.
Roca-Ferrer J, Garcia-Garcia FJ, Pereda J, Perez-Gonzalez M, Pujols L, Alobid I, et al. Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma. J Allergy Clin Immunol. 2011;128(1):66–72 e61.CrossRefPubMed
25.
Ying S, Meng Q, Scadding G, Parikh A, Corrigan CJ, Lee TH. Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J Allergy Clin Immunol. 2006;117(2):312–8.CrossRefPubMed
26.
Machado-Carvalho L, Martin M, Torres R, et al. Low E-prostanoid 2 receptor levels and deficient induction of the IL-1beta/IL-1 type I receptor/COX-2 pathway: vicious circle in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(1):99–107 e107.CrossRefPubMed
27.
28.
Liu T, Kanaoka Y, Barrett NA, et al. Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway. J Immunol. 2015;195(8):3537–45.CrossRefPubMed
29.
Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1566–s.CrossRefPubMed
30.
Ta V, White AA. Survey-defined patient experiences with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(5):711–8.CrossRefPubMed
31.
Laidlaw TM, Fuentes DJ, Want Y. Efficacy of zileuton in patients with asthma and history of aspirin sensitivity: a retrospective analysis of data from two phase 3 studies. J Allergy Clin Immunol. 2017;139(2):1.CrossRef
32.
McMains KC, Kountakis SE. Medical and surgical considerations in patients with Samter's triad. Am J Rhinol. 2006;20(6):573–6.CrossRefPubMed
33.
Rozsasi A, Polzehl D, Deutschle T, et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008;63(9):1228–34.CrossRefPubMed
34.
Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003;111(1):180–186.
35.
Cahill KN, Cui J, Kothari P, Murphy K, Raby BA, Singer J, et al. Unique effect of aspirin therapy on biomarkers in aspirin-exacerbated respiratory disease. A prospective trial. Am J Respir Crit Care Med. 2019;200(6):704–11.CrossRefPubMedPubMedCentral
36.
Schneider TR, Johns CB, Palumbo ML, Murphy KC, Cahill KN, Laidlaw TM. Dietary fatty acid modification for the treatment of aspirin-exacerbated respiratory disease: a prospective pilot trial. J Allergy Clin Immunol Pract. 2018;6(3):825–31.CrossRefPubMed
37.
Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22–209.PubMed
38.
Jerschow E, Edin ML, Chi Y, et al. Sinus surgery is associated with a decrease in aspirin-induced reaction severity in AERD patients. J Allergy Clin Immunol Pract. 2018.
39.
Huang GX, Palumbo ML, Singer JI, Cahill KN, Laidlaw TM. Sinus surgery improves lower respiratory reactivity during aspirin desensitization for AERD. J Allergy Clin Immunol Pract. 2019;7(5):1647–1649.
40.
Rudmik L, Soler ZM, Hopkins C, Schlosser RJ, Peters A, White AA, et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Int Forum Allergy Rhinol. 2016;6(6):557–67.PubMed
41.
Lothrop HA. XIV. Frontal sinus suppuration: the establishment of permanent nasal drainage; the closure of external fistulae; epidermization of sinus. Ann Surg 1914;59(6):937–957.
42.
Timothy LS. The endoscopic modified Lothrop procedure: finally ready for prime time in the management of inflammatory sinus disease. Int Forum Allergy Rhinol. 2016;6:549.
43.
Barham HP, Ramakrishnan VR, Knisely A, Do TQ, Chan LS, Gunaratne DA, et al. Frontal sinus surgery and sinus distribution of nasal irrigation. Int Forum Allergy Rhinol. 2016;6(3):238–42.PubMed
44.
Naidoo Y, Bassiouni A, Keen M, Wormald PJ. Long-term outcomes for the endoscopic modified Lothrop/Draf III procedure: a 10-year review. Laryngoscope. 2014;124(1):43–9.CrossRefPubMed
45.
Morrissey DK, Psaltis AJ, Wormald P-J. Outcomes of modified endoscopic Lothrop in aspirin-exacerbated respiratory disease with nasal polyposis. Int Forum Allergy Rhinol. 2016;6:820–5.PubMed
46.
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–84.CrossRefPubMedPubMedCentral
47.
Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200 e120.CrossRefPubMed
48.
Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59.CrossRefPubMed
49.
Tuttle KL, Buchheit KM, Laidlaw TM, Cahill KN. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2018;6(3):1045–7.CrossRefPubMedPubMedCentral
50.
Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–995 e981–988.CrossRefPubMed
51.
Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024–1031 e1014.CrossRefPubMed
52.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96.CrossRefPubMed
53.
Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–85.CrossRefPubMed
54.
Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–79.CrossRefPubMed
55.
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–50.CrossRefPubMed
56.••
Laidlaw TM, Mullol J, Fan C, Zhang D, Amin N, Khan A, et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. J Allergy Clin Immunol Pract. 2019;7(7):2462–5 e2461. Study showing that dupilumab can reduce nasal polyp burden and improve sense of smell, asthma control and quality of life in patients with AERD.
57.
Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–46.CrossRefPubMed
58.
Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–10.CrossRefPubMed
59.
Kupczyk M, Kurmanowska Z, Kuprys-Lipinska I, Bochenska-Marciniak M, Kuna P. Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge. Respir Med. 2010;104(10):1404–9.CrossRefPubMed
60.
Liu T, Garofalo D, Feng C, et al. Platelet-driven leukotriene C4-mediated airway inflammation in mice is aspirin-sensitive and depends on T prostanoid receptors. J Immunol. 2015;194(11):5061–8.CrossRefPubMed
61.
Liu T, Barrett NA, Kanaoka Y, et al. Cysteinyl leukotriene receptor 2 drives lung immunopathology through a platelet and high mobility box 1-dependent mechanism. Mucosal Immunol. 2019;12(3):679–90.CrossRefPubMedPubMedCentral
Metadata
Title
NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets
Authors
Tanya M. Laidlaw
Joshua M. Levy
Publication date
01-04-2020
Publisher
Springer US
Published in
Current Allergy and Asthma Reports / Issue 4/2020
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-020-00905-9